Navigation Links
Cornerstone Therapeutics to Host Fourth Quarter and Full-Year 2009 Conference Call
Date:2/18/2010

used on acquiring, developing and commercializing significant products primarily for the respiratory and related markets. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with a recent regulatory submission filing and four additional regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force which is focused on the respiratory and related markets; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein, other than statements of historical fact, including statements regarding the progress and timing of our product development programs and related trials, our strategy and our future operations and opportunities, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of preclinical studies and clinical trials with respect to our products under development, our ability to satisfy FDA and other regulato
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference
2. Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference
3. Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call
4. Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive(R)
5. Cornerstone Therapeutics Announces Closing of Chiesi Transaction
6. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
7. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
8. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
9. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
10. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
11. 3SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... York, NY (PRWEB) December 16, 2014 ... significant changes since 2013, which is why IBISWorld updated ... this industry continues to benefit from an intensified focus ... the proposal for new emission standards for power plants ... industry operators. According to IBISWorld Industry Analyst Sarah Kahn, ...
(Date:12/17/2014)... Washington, USA (PRWEB) December 16, 2014 ... Baum, manager at Philipps- Universität Marburg’s Department of ... and photonics, in the newly released SPIE ... “And never be too shy to ask questions.” ... (science, technology, engineering, and mathematics) occupations ranging from ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
(Date:12/17/2014)... December 17, 2014 This report ... Quartz Tubing industry. For an overview analysis, the ... application, industry chain structure, industry overview, policy analysis, ... tubing industry has witnessed rapid development with ... of acquisitions. This report mentions quartz tubing upstream ...
Breaking Biology Technology:Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 82020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2
... Company to Provide Business Systems and Technology Support to NIH Office ... ... 5 SRA International, Inc.,(NYSE: SRX ), a leading provider ... has been,awarded a competitive task order to provide a broad range ...
... Oct. 5 The Coalition for a,Competitive Pharmaceutical ... Food and Drug Administration,s announcement regarding its,"Generic Initiative ... employers, insurers, and policymakers grappling with,how to manage ... FDA,and Congress continue to focus on ways to ...
... Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) today announced ... executive officer, will present,at the BIO InvestorForum at The ... 2007 at 11:00 a.m. Pacific Time. A live ... website at http://www.lexpharma.com . An archived version of ...
Cached Biology Technology:National Institutes of Health Awards $25.5M Contract to SRA 2CCPM Issues Statement on FDA's GIVE Initiative 2Lexicon Pharmaceuticals to Present at Bio InvestorForum 2
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ... expand its team and bring LaunchKey to market in ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB ... Good Clinical Practices (GCP) audit to confirm its ... (FDA) regulations. This accomplishment enables HITLAB to conduct ... utilizing the highest principles for patient safety and ... improve global healthcare access, quality, and delivery with ...
(Date:12/17/2014)... 16, 2014  Automation is fundamentally transforming the ... than at international borders. Over the past decade, ... allowed veteran travelers to self process through border ... Kiosks at an increasing number of airports, seaports, ... According to Maxine Most , Principal ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... of vocal mimicry, researchers from the Wildlife Conservation Society (WCS) ... cat species imitating the call of its intended victim: a ... the first recorded instance of a wild cat species in ... extraordinary behavior was recorded by researchers from the Wildlife Conservation ...
... leave the pediatrician,s office if your child has strep ... treatment. A novel application for applying DNA "nanobarcodes" ... and more accurately determine what,s causing a patient,s acute ... R. Hartman, a Cornell University PhD candidate in Biological ...
... Elsevier, a world leader in health care, medical publishing ... Legacy Interactive, announced today the release of Top Doc, ... designed to let medical students, residents and junior faculty ... and Legacy Interactive developed the app,s interactive format to ...
Cached Biology News:Wildlife Conservation Society finds wild cat mimicking monkey calls 2Instant testing for sore throats wins CIMIT prize 2Instant testing for sore throats wins CIMIT prize 3Instant testing for sore throats wins CIMIT prize 4Elsevier and Legacy Interactive partner to launch iPhone app 2
...
Experion spin filters are used to filter the gel matrix and gel stain solution prior to use with the Experion automated electrophoresis system. Supplied as 10 spin filters....
...
... to PRKAR2 cAMP is a signaling ... functions. cAMP exerts its effects by activating ... the signal through phosphorylation of different target ... a tetramer composed of two regulatory and ...
Biology Products: